Review
Published on 17 Jan 2024
Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1325255
- 216 views
Type at least 3 characters
5,330 articles
Articles
Review
Published on 17 Jan 2024
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1285895
- 216 views
Original Research
Published on 17 Jan 2024
Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1301157
- 201 views
Original Research
Published on 17 Jan 2024
Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1301945
- 228 views
Review
Published on 17 Jan 2024
Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1281744
- 265 views
Review
Published on 17 Jan 2024
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1328145
- 207 views
Original Research
Published on 17 Jan 2024
The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1331287
- 324 views
Systematic Review
Published on 17 Jan 2024
Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1302840
- 161 views
Review
Published on 17 Jan 2024
Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1344821
- 144 views
Case Report
Accepted on 16 Jan 2024
Case Report: The Utilization of Crizotinib and Brentuximab Vedotin as a Bridge to Autologous Stem Cell Transplantation and Followed by CD30-directed CAR-T Cell Therapy in Relapsed/Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1346001
Case Report
Accepted on 16 Jan 2024
Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: A case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1360671
Correction
Accepted on 16 Jan 2024
Arachidonate 15-lipoxygenase mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell induced cancer cell invasion
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1353835
Systematic Review
Accepted on 16 Jan 2024
Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: A meta-analysis and systematic review
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1339757
Original Research
Accepted on 16 Jan 2024
Location matters: spatial dynamics of tumor-infiltrating T cell subsets is prognostic in colon cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1293618
Correction
Accepted on 16 Jan 2024
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1365240
Correction
Published on 16 Jan 2024
Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1365027